| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
SureSwab® Advanced Bacterial Vaginosis (BV), CT/NG, TMA : 10123
Test CodeCGBV or 10123
CPT Codes
81513, 87491, 87591
Includes
Bacteria associated with bacterial vaginosis (BV), including Lactobacillus (L. gasseri, L.crispatus, and L. jensenii), Gardnerella vaginalis, and Atopobium vaginae.
and
Chlamydia trachomatis and Neisseria gonorrhoeae
and
Chlamydia trachomatis and Neisseria gonorrhoeae
Transport Container
Vaginal swab: Follow instructions in the Aptima® Multitest Collection Kit (orange label).
Transport Temperature
Room temperature.
Specimen Stability
Swabs in Aptima® Transport:
Room temperature: 30 days; Refrigerated: 30 days; Frozen: 6 months
Room temperature: 30 days; Refrigerated: 30 days; Frozen: 6 months
Methodology
Transcription-Mediated Amplification (TMA)
Setup Schedule
Monday - Saturday
Report Available
1-3 days
Reference Range
NOT DETECTED
Bacterial Vaginoisis: NEGATIVE
Bacterial Vaginoisis: NEGATIVE
Clinical Significance
The assay is intended to aid in the diagnosis of Bacterial vaginosis (BV), and Chlamydia trachomatis/ Neisseria gonorrhoeae using clinician-collected and patient-collected vaginal swab specimens from individuals with a clinical presentation consistent with vaginitis and/or vaginosis.
The BV test is an in vitro nucleic acid amplification test that utilizes real time transcription-mediated amplification (TMA) for detection and quantitation of ribosomal RNA from bacteria associated with bacterial vaginosis (BV), including Lactobacillus (L. gasseri, L.crispatus, and L. jensenii), Gardnerella vaginalis, and Atopobium vaginae. The assay reports a qualitative result for BV and does not report results for individual organisms.
For C. trachomatis and N. gonorrhoeae,
A target capture assay for the in vitro qualitative detection and differentiation of ribosomal RNA from Chlamydia trachomatis and/or Neisseria gonorrhoeae by transcription-mediated amplification (TMA) is utilized.
The BV test is an in vitro nucleic acid amplification test that utilizes real time transcription-mediated amplification (TMA) for detection and quantitation of ribosomal RNA from bacteria associated with bacterial vaginosis (BV), including Lactobacillus (L. gasseri, L.crispatus, and L. jensenii), Gardnerella vaginalis, and Atopobium vaginae. The assay reports a qualitative result for BV and does not report results for individual organisms.
For C. trachomatis and N. gonorrhoeae,
A target capture assay for the in vitro qualitative detection and differentiation of ribosomal RNA from Chlamydia trachomatis and/or Neisseria gonorrhoeae by transcription-mediated amplification (TMA) is utilized.
Performing Laboratory
med fusion
